Proprietary CoupledCAR™ platform
Our unique CoupledCAR™ platform is designed to overcome the common challenges of treating solid tumors.It enables in vivo expansion of CAR-T cells, significantly enhancing the efficacy of CAR-T therapy for metastatic solid tumors—a major breakthrough in the field.
GCC19CART, the leading product being developed to treat patients with R/R mCRC
In the dose-escalation study conducted in China, at dose level 2 (2 x 10^6 CAR-T/kg), the ORR was observed to be 50%, with the mOS exceeding 26 months.
Our lead program, GCC19CART, has demonstrated robust clinical activity in treating relapsed/refractory metastatic colorectal cancer (mCRC), with promising data from clinical trials in both China and the United States. GCC19CART has the potential to become the First-in-Class CAR-T product globally approved for the treatment of colorectal cancer.
Phase 1 study of GCC19CART is enrolling patients with R/R mCRC in the U.S., at dose level 1(1 x 10^6 CAR-T/kg), among four patients, the objective response rate (ORR) was 50%, with a median overall survival (mOS) of 17 months. At dose level 2(12x 10^6 CAR-T/kg), among five patients, the ORR was 80%, and the mOS has not yet been reached.
The broad pipeline of CAR-T candidates targeting other solid tumor
We’re also expanding our CAR-T candidate portfolio to treat more types of solid tumors, such as prostate cancer（mCRPC）.
INSTACAR™, our integrated platform supporting CAR-T innovation
INSTACAR™ is ICT’s proprietary platform that enables key service capabilities essential for advancing personalized cellular therapies, including cryopreservation, immunotherapy research and development, medical diagnostics, and scientific research.
ARMOREDCAR™, our engineered enhancement platform for next-generation CAR-T therapies
ARMOREDCAR™ is ICT’s proprietary engineering framework designed to strengthen cellular therapies through targeted functional enhancements. The platform supports research and development in immunotherapy by enabling controlled cytokine modulation, improved tumor microenvironment resilience, and optimized CAR-T performance for advanced scientific and translational applications.
Better CAR-T Therapy for Solid Tumors
Discover our broad pipeline of CAR-T candidates targeting other solid tumors
